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ABSTRACT
There has been some concern among parents and in the media that vaccinating children against human
papillomavirus could be seen as giving children permission to engage in risky sexual behaviors (also
known as sexual disinhibition). Several studies have found this concern to be unfounded but there have
been no attempts to synthesize the relevant studies in order to assess if there is evidence of sexual
disinhibition. The aim of this study was to synthesize recent literature examining sexual behaviors and
biological outcomes (e.g., sexually transmitted infections) post-HPV vaccination. We reviewed literature
from January 1, 2008-June 30, 2015 using PubMed, CINAHL, and Embase with the following search terms:
[(sex behavior OR sex behavior OR sexual) AND (human papillomavirus OR HPV) AND (vaccines OR vaccine
OR vaccination)] followed by a cited reference search. We included studies that examined biological
outcomes and reported behaviors post-vaccination in both males and females. Studies were reviewed by
title and abstract and relevant studies were examined as full-text articles. We identiﬁed 2,503 articles and
20 were eventually included in the review. None of the studies of sexual behaviors and/or biological
outcomes found evidence of riskier behaviors or higher rates of STIs after HPV vaccination. Instead, the
studies found that vaccinated compared to unvaccinated individuals were less likely to report vaginal
intercourse without a condom (OR D 0.5; 95%CI D 0.4–0.6) and non-use of contraception (OR D 0.27;
95%CI D 0.15–0.48) and unvaccinated participants had higher rates of Chlamydia (OR D 2.3; 95%CI D
1.06–5.00). These results should be reassuring to parents and health care providers.
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Introduction
In 2015, the Centers for Disease Control and Prevention (CDC)
reported that there are approximately 79 million Americans
who are currently infected with Human Papillomavirus (HPV)
and 14 million new infections occur every year, making it the
most common sexually transmitted infection (STI).1 It is esti-
mated that the worldwide prevalence of HPV infection in
women without cervical abnormalities is 11–12%. This varies
by region with higher rates in sub-Saharan Africa (24%), East-
ern Europe (21%) and Latin America (16%).2 Infection with
HPV is a risk factor for serious health issues including genital
warts, cervical cancer, anal cancer, penile cancer, oropharyngeal
cancers, and recurrent respiratory papillomatosis.1 Currently,
there are 3 different HPV vaccines: 1) A bivalent vaccine
(2vHPV) that protects against HPV types 16 and 18, 2 types
that are responsible for about 70% of cervical cancer diagno-
ses;3 2) A quadrivalent vaccine (4vHPV) that protects against
HPV-16 and 18 as well as HPV-6 and 11, 2 types that cause
about 90% of the cases of genital warts;4 and 3) A nine-valent
HPV vaccine (9vHPV) was recently licensed by the US. Food
and Drug Administration, and protects against the 4 HPV
types in 4vHPV as well as 5 additional oncogenic types (HPV
types 31, 33, 45, 52, and 58). 9vHPV has the potential to pre-
vent 80–90% of cervical cancers, and many vulvar, vaginal, and
anal cancers in addition to 90% of genital warts.5
Despite the recommendations made by national immuniza-
tion advisory committees around the world, HPV vaccination
rates, especially in the United States, remain suboptimal.6,7 For
example, only 60.0% of adolescent girls and 41.7% of adolescent
boys between the ages of 13 and 17 received one or more doses
in the HPV vaccine series in the United States in 2014.8 These
rates are even lower when examining the percentages of adoles-
cents who have completed the series, which is necessary in
order to receive the maximum protection from the vaccine.9
Several barriers to HPV vaccination exist including cost of the
vaccination, lack of knowledge about HPV transmission, and
parental concerns about vaccinating their children against an
STI.10
One concern among parents, clinicians, and public health
ofﬁcials, which has received particular attention in the media,
is that the introduction of the HPV vaccine will lead to risk
compensation, a concept introduced by Wilde in the 1980s that
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he called Risk Homeostasis Theory (RHT).11 RHT suggests that
individuals have innate set points for risk tolerance and that
they change their behaviors based on perceived risk in order to
maintain their set point. According to RHT, then, if an individ-
ual believes that a measure protects him/her from a certain
risk, then he/she would be more likely to engage in risky behav-
iors.11 Critics of the HPV vaccine have expressed concern that
the receipt of the vaccine could cause adolescents to engage in
riskier sexual behavior due to perceived protection from sexu-
ally transmitted infections.12 This is a concern that has arisen
throughout the world. For example, several Roman Catholic
bishops in Canada discouraged vaccination, stating that
school-based vaccination “sends a message that early sexual
intercourse is allowed”13 and that abstinence is the “only truly
healthy choice.”14,15 One study using qualitative interviews of
mothers in the United Kingdom found it described as giving
girls a “carte blanche” to engage in behaviors that put them at
risk for pregnancy, HIV, and STIs.16
These parental concerns might have been inﬂuenced by sto-
ries they encountered in the media.17-19 A US study found a
majority of news articles about HPV vaccination were neutrally
toned but the results also indicated that there were several
important informational facts that were omitted in the articles,
namely information about side effects, duration of protection,
and information about catch-up vaccination.20 Internet use and
accuracy of internet information regarding the HPV vaccine
are important considerations because some studies have found
that vaccine concerns can be inﬂuenced by negative (and often
inaccurate) media reports.21 Media reports and inaccurate
information could cause parents concern prior to getting their
children vaccinated, speciﬁcally in regard to risk compensation.
Across several studies between 16% and 26% of parents indi-
cate that they were concerned that HPV vaccination would
increase the likelihood that their child would engage in riskier
sexual behavior.22-25 However, this worry about sexual disinhi-
bition was not usually listed as a reason for non-vaccination,
and only 3–6% of parents cited this concern as a reason for
refusing vaccination.26,27
The objective of the present study was to conduct a system-
atic review of research literature to evaluate whether there is
evidence (via either self-report of sexual behaviors or biological
outcomes such as sexually transmitted infections) of sexual dis-
inhibition following HPV vaccination. Our aims were to
answer the following research questions: 1) Is there consistent,
replicated evidence of increased self-reported risky sexual
behaviors after HPV vaccination? and 2) Is there consistent,
replicated evidence of increased incidence of sexually transmit-
ted infections or pregnancies after HPV vaccination?
Results
Study characteristics
The initial search of the 3 databases resulted in 2,503 returns.
Once duplicates were deleted, 1,584 articles remained. After
screening by title and abstract, there were 29 full-text articles to
be reviewed by all of the authors. The ﬁnal selection resulted in
20 articles being included in the study. For the full PRISMA
ﬂow diagram, see Figure 1.
Of the 20 studies included in the systematic review, 2 were
qualitative, 12 were cross-sectional, and 8 were longitudinal
studies. It is important to note that these categories are not
mutually exclusive. If a study used more than one study design
and the results were presented separately, it was counted in
both relevant categories. Although we searched for studies
between 2008 and 2015, the relevant studies for this review
were published between 2011 and 2015. Furthermore, although
we did not restrict by age or gender, all of the studies examined
exclusively female populations and all of them studied popula-
tions within the 10 to 46 year-old age range. The descriptive
statistics of the included studies are reported in Table 1. The
full list of qualitative, cross-sectional, and longitudinal study
results from the review are included as Tables 2, 3, and 4,
respectively.
Critical appraisal of the studies
The 20 studies were divided among all of the co-authors, such
that each study was reviewed by 2 co-authors, who then ﬁlled
out corresponding data extraction sheets (the data extraction
sheet used for this study is provided as the Appendix). The
data extraction sheet contained items from previously validated
data quality assessment tools including the Agency for Health-
care Research and Quality’s (AHRQ), Cochrane, PRISMA, and
the NIH Quality Assessment Tool for Observational Cohort
and Cross-Sectional Studies. Items on the data extraction sheet
included assessment of study design, inclusion/exclusion crite-
ria, study population and comparison group, length of follow-
up, outcomes, limitations, generalizability, and an assessment
of overall study quality. Overall study quality was assessed by
each coauthor on a scale of 1–10 with higher numbers indicat-
ing greater study quality. The authors were given criteria with
which to judge the studies and if the quality assessment from
each author varied by more than 2 points, disagreements were
resolved through discussion. The study’s quality score was then
averaged between the 2 reviewers’ scores. Average study quality
score ranged from 1.8 to 9.0 (mean D 6.2; standard deviation D
2.0).
Behavioral outcomes
All but 3 studies examined self-reported behavioral outcomes
(n D 17, 85%). A widely studied behavior was sexual activity,
which was assessed in many of the studies included in the
review (n D 12) but was only statistically evaluated in 10 of the
studies. Sexual activity was deﬁned differently across studies,
and included reported sexual intercourse any time after receipt
of HPV vaccine (or any time after 10 y of age for the unvacci-
nated controls),28 ever having sex with someone of the opposite
sex,29 and any experience of intercourse.30,31 Other behaviors
examined in the studies were: age at sexual debut (nD 7), num-
ber of sexual partners (n D 13), use of contraception (n D 16),
and other sexual risk behaviors (n D 5).
Self-reported sexual activity
One study by Aujo et al. (2014) used both qualitative and quan-
titative methods to examine self-reported sexual activity in 2
different communities (one vaccinated and one unvaccinated
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community) in Uganda.28 The qualitative component of the
study found that most girls indicated they were not engaged in
sexual activity themselves but they knew of others who were.
The cross-sectional survey portion of the study found that
young girls engaged in sexual activity in both the vaccinated
and unvaccinated districts, but vaccinated girls had a lower
reported rate of sexual intercourse than unvaccinated girls
(1.5% vs. 2.5%).28
The majority of the studies examining self-reported sex-
ual activity were cross-sectional in nature and some of these
cross-sectional studies did ﬁnd that vaccinated participants
were more likely to have engaged in sexual intercourse than
unvaccinated participants.30,32,33 However, these studies also
noted that many of their participants (between 45% and
62%) were sexually active prior to HPV vaccination.29,30
Due to the cross-sectional nature of these studies, these
results may be more indicative of a woman engaging in
sexual behavior and then seeking out protective measures as
opposed to the vaccination causing the increased sexual
behavior. Furthermore, previous studies have shown that
providers are more likely to offer or strongly recommend
the vaccine to patients they believe are sexually active or
are not in a monogamous relationship.34-36 Other cross-sec-
tional studies found no statistical difference in sexual
activity between vaccinated and unvaccinated participants
(odds ratios between 0.88 and 1.07).37-40
The longitudinal studies did not demonstrate that vacci-
nated women were more sexually active than unvaccinated
women when post-vaccination behavior change was assessed.
Some of these studies found that there was no statistically sig-
niﬁcant difference in baseline to follow-up sexual activity
between vaccinated and unvaccinated women,37,41,42 while
others found decreases in sexual activity after vaccination. One
study of female sex workers conducted by Brown et al. (2013)
in Peru found female sex workers decreased sexual activity with
all clients after vaccination (p < 0.001).43 And another study
(Mayhew et al., 2014) of a fully vaccinated sample found that
participants between 16 and 21 y of age who inappropriately
perceived lower risk for non-HPV STIs after vaccination were
actually less likely to initiate sex over the following 6 month
period (OR D 0.13; 95% CI D 0.03–0.69).31
Figure 1. PRISMA ﬂow diagram.
Table 1. Descriptive statistics and quality assessment.
Total Studies (20) N (%)
Study Design
Qualitative 2 (10%)
Cross-Sectional 12 (60%)
Cohort 8 (40%)
Used Unvaccinated Control Group 16 (80%)
Outcome Assessed
Behavioral 17 (85%)
Reported Sexual Activity 12 (60%)
Age at Sexual Debut 7 (35%)
Number of Partners 13 (65%)
Contraception Use 16 (80%)
Biological 9 (45%)
STI Testing/Diagnosis 6 (30%)
Pregnancy/Abortion/Composite Measure 5 (25%)
Average Study Quality Score (1-10) 6.2
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Self-reported age at sexual debut
Seven of the studies examined age at ﬁrst intercourse as a risky
behavior post-vaccination. The studies deﬁned the variable dif-
ferently with some looking at age as a continuous variable and
some categorizing the variable as sexual debut before or after a
certain age (usually 15 or 16). Regardless of how the variable
was deﬁned, none of the studies that examined age at sexual
debut found a statistically signiﬁcant difference between vacci-
nated and unvaccinated groups.29,33,38,44-46 Only one study
(Liddon et al., 2012) found an association between HPV vac-
cine and age at ﬁrst intercourse. But this was only signiﬁcant in
the bivariate model of a subset of 20–24 y olds and was not sig-
niﬁcant in the multivariable model.39
Self-reported number of sexual partners
Most of the studies examining the number of sexual partners
between groups found no association between vaccination sta-
tus and number of partners. This result held true in cross-sec-
tional studies when the researchers examined number of
lifetime partners,29,33,37-40,44,45 number of partners in the last
12 months,44 and number of partners before 18 y of age.38 It
also held true in studies that followed cohorts longitudinally,
which found vaccinated women did not have more sexual part-
ners at follow-up.37,41,42 A Mayhew et al. (2014) study of a fully
vaccinated sample did not see a signiﬁcant increase in the num-
ber of sexual partners after the sample was vaccinated.31
In fact, some of the studies found that vaccinated women
had fewer sexual partners than unvaccinated women. One pop-
ulation-based study of Nordic women (Hansen et al., 2014)
found that women who were vaccinated opportunistically (i.e.,
those that were vaccinated but not during an organized vacci-
nation program) were signiﬁcantly less likely than unvaccinated
participants to have had 4 or more partners before reaching age
18 (AOR D 0.56; 95% CI D 0.40-0.78).38 A similar ﬁnding was
reported in a study conducted by Sadler et al. (2015) in the
United Kingdom that found that non-vaccination was posi-
tively associated with having 3 or more partners in the last
6 months (OR D 2.12; 95% CI D 1.08-4.17).46 A study con-
ducted by Lutringer-Magnin et al. (2013) in France, found that
vaccinated girls between the ages of 17 and 20 had had fewer
partners than unvaccinated girls (p D 0.01).40 Furthermore, a
study of Peruvian female sex workers by Brown et al. (2013)
found that participants had a signiﬁcantly lower frequency of
intercourse with new clients after vaccination (p < 0.001).43
Use of contraception
Several of the studies examined use of contraception. Some
assessed condom use while others examined use of hormonal
contraception or counseling on contraception. While there
has been some concern that an erroneous belief that the
HPV vaccine protects against all STIs would result in a
decrease in condom use, a study examining risk perceptions
found that this erroneous belief did not result in decreased
condom use.31 A qualitative study by Ports et al. (2014)
found that none of the women they interviewed reported
that the HPV vaccine had an inﬂuence on their use of con-
doms during sexual activity.47 Cross-sectional studies assess-
ing condom use utilized different deﬁnitions for their studies
including an assessment of general condom use,30,44,45 con-
sistent condom use in the last month,39 condom use during
most recent intercourse,40 condom use during ﬁrst inter-
course,40,48 and consistent condom use during all sexual
encounters.29,32,33,44 Regardless of how condom use was
deﬁned, none of the aforementioned studies found any sta-
tistically signiﬁcant relationship between HPV vaccination
and condom use. However, some studies did note that vacci-
nated women were more likely to take protective measures
and found a positive association between condom use and
vaccination. A study by Hansen et al. (2014) found that non-
use of contraception during ﬁrst intercourse was signiﬁcantly
less frequent among women who were vaccinated before sex-
ual debut as opposed to their matched unvaccinated counter-
parts (ORD0.27; 95%CID0.15-0.48 for those vaccinated
during an organized vaccination program; ORD0.69;
95%CID0.52-0.93 for those vaccinated opportunistically).38
Liddon et al. (2012) found that a higher percentage of those
who reported always or at least inconsistently using condoms
reported being vaccinated as opposed to those who never
used condoms.39 Ruiz-Sternberg et al. (2014) reported a sim-
ilar ﬁnding, that vaccinated women were more likely to
report consistent condom use than unvaccinated women.33
Additionally, Sadler et al. (2015) reported condom use at
Table 2. Qualitative studies.
First author, year,
location
Data collection method, date Participant details Analysis Primary Findings
Aujo, 2014, Uganda Semi-structured focus groups,
date unclear
52 girls aged 12-15 y old Thematic analysis Vaccinated and unvaccinated girls
engaged in sexual activity. Effect
vaccination might have on sexual
behaviors had varying responses.
Ports, 2014, United States Semi-structured individual
phone interviews, 2013
30 women 19-25 y old (mean
age=28.87), received all 3 HPV
vaccine doses
Thematic analysis 83% said that having been
vaccinated against HPV had no
inﬂuence on their romantic
relationships and did not have
any effect on their participation in
safer sex (50%). 27% reported that
getting vaccinated made them
more aware of sexually
transmitted diseases, and more
cautious with sexual activity.
 Aujo et al. (2014) utilized both qualitative and cross-sectional study designs and as such is listed in both tables. Only the results from the qualitative portion of the study
are reported in this table.
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ﬁrst intercourse was positively associated with HPV vaccina-
tion (OR D 0.55; 95%CI D 0.32-0.96).48 There were 2 studies
that examined use of emergency hormonal contraception
(Lutringer-Magnin et al., 2013 and Sadler et al., 2015). Nei-
ther study found any differences in the use of emergency
contraception between those who had been vaccinated and
those who had not.40,48
Contraceptive behavior was also examined by several studies
longitudinally. Bednarczyk et al. (2012) used data from a man-
aged care organization to assess the relationship between a
patient seeking counseling on contraceptives and HPV vaccine.
This study found that vaccinated participants were more likely
to seek counseling on contraceptive use as opposed to unvacci-
nated participants, although the adjusted incident rate ratio
was not signiﬁcant (OR=2.31; 95%CI D 0.99-5.38).49 This
result is consistent with a study by Forster et al. (2012) that
found no change in condom use from baseline to follow up by
vaccination group (OR=0.88; 95%CI D 0.58-1.33).37 A study of
female sex workers found no change in condom use with all cli-
ents after vaccination but they did note that condom use with
non-paying partners increased, although not signiﬁcantly (p D
0.38).43 Another longitudinal study (Cummings et al., 2012)
found instances of vaginal intercourse without a condom over
the last 2 months was signiﬁcantly lower in the vaccinated
group (p < 0 .001).41 The ﬁndings from all of the studies com-
bined demonstrated that there was either no association
between HPV vaccination and condom use/contraception
counseling or they demonstrated that vaccinated participants
engaged in safer behaviors than unvaccinated participants.
Other risk behaviors
Many of the included studies also examined risky behaviors
that did not ﬁt in the above categories. Several of the studies
examined relationship status. Most of them deﬁned being in a
monogamous relationship as a “safe” behavior and being in
non-exclusive relationships or having one-night stands as con-
stituting “unsafe” behavior. One study conducted in Uganda
that used dating and sexual activity as measures of risky behav-
ior found that unvaccinated girls were dating at higher rates
than vaccinated girls (5% vs. 2.5%) but the authors did not
assess if those speciﬁc dating relationships involved risky sexual
behaviors.28 Another study (Mather et al., 2012) compared
“safe sexual behavior” between vaccinated and unvaccinated
individuals by creating a composite measure that included con-
dom use, use of other contraception, and having been in a
monogamous relationship for at least 3 months. Using this
measure, authors found no relationship between HPV vaccina-
tion and engaging in safe sexual behavior.32 Rysavy et al. (2014)
used a similar technique to examine “high risk sexual behav-
iors” such as frequency of condom use, number of partners, as
well as experience of anal and oral intercourse and age at ﬁrst
anal and oral intercourse to create a risk behavior score. This
study found that there were no differences between the vacci-
nated and unvaccinated groups on the composite risk behavior
score.45 This relationship was still not signiﬁcant when the high
risk behaviors were examined individually. Another study
(Mattebo et al., 2014) examined high risk behaviors individu-
ally and assessed the effect of experiencing one-night stands,
group sex, “friends with beneﬁts” relationships, oral sex, and
anal sex. In this study the authors did ﬁnd that vaccinated
women were more likely to have experienced a one-night stand
(p D 0.046) but this cross-sectional study noted that 62% of
their sample had reached sexual debut before vaccination so
the temporal relationship between sexual experience and vacci-
nation cannot be assessed and it is possible a person engaging
in high-risk sexual behaviors was more likely to seek vaccina-
tion.30 Furthermore, this study found no differences when com-
paring vaccinated and unvaccinated individuals with respect to
experiencing a “friends with beneﬁts” relationship, group sex,
giving oral sex, receiving oral sex, or anal sex.30 Lastly, a cross-
sectional study examined several risk behaviors including anal
intercourse, sexual experiences abroad, use of drugs or alcohol,
and being a current smoker. Among other risk behaviors previ-
ously discussed (i.e., contraception use, number of partners,
etc.) this study found that the unvaccinated group was more
likely to have experienced anal intercourse as their last sexual
contact (OR D 4.43; 95%CI D 1.23-14.29) and to be a current
smoker.48 Smoking status is an important factor to examine
because smoking is a risk factor for cervical cancer, even when
controlling for the effects of HPV infection and other potential
cofactors.50,51
Biological outcomes
Along with reporting behavioral outcomes, several studies also
examined biological outcomes (n D 9, 45%). For the purposes
of this review, they have been divided into two general catego-
ries: STI testing/diagnosis and pregnancy (including a compos-
ite measure of STI and pregnancy)/abortions.
STI/HIV testing or diagnosis
All of the studies in this subset had some measure of STI testing
or diagnosis. Of the studies that examined STI or HIV testing
or diagnosis, none of them found HPV vaccination to increase
STI rates. Of the cross-sectional studies, one (Liddon et al.,
2012) found no association between HPV vaccination and
receiving STI services in the past year in both the 15-19 and the
20-24 y old age groups.39 Two cross-sectional studies examin-
ing reported STI diagnoses30,45 and one examining HIV serol-
ogy48 all found no signiﬁcant differences between the
vaccinated and unvaccinated groups. Additionally, one study
(Sadler et al., 2015) found that unvaccinated women were more
likely to have received a positive Chlamydia trachomatis diag-
nosis (OR D 2.3; 95% CI D 1.06-5.00).48
Two longitudinal studies (Cummings et al., 2012 and Jena
et al., 2015) examined the association between STIs and HPV
vaccination.41,52 One longitudinal study by Jena et al. (2015)
found that the difference-in-difference odds ratios in the year
after vaccination was similar between the vaccinated and
unvaccinated groups.52 This held true for both the 12 to 14 and
the 15 to 18 year-old groups. Another cohort study found no
differences in Chlamydia or Trichomonas infection rates
between vaccinated and matched unvaccinated groups.41
Abortion/Pregnancy or a composite measure of STI and
pregnancy
Several studies used composite measures of STI diagnosis and
pregnancies. One cohort study (Bednarczyk et al., 2012) looked
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at a composite measure of testing or diagnosis of Chlamydia
trachomatis infection, pregnancy, or venereal disease not other-
wise speciﬁed (referred to as testing/diagnosis/counseling)
found that girls receiving HPV vaccine did not have signiﬁ-
cantly higher rates of testing/diagnosis/counseling. They found
the same results when they examined diagnosis-only rates
between vaccinated and unvaccinated groups.49 Another cohort
study (Smith et al., 2015) found no statistically signiﬁcant
increase in a composite measure of STIs and pregnancy in rela-
tion to HPV vaccination. This result held true when STIs and
pregnancy were examined separately as well.53
Studies also examined pregnancy and abortions individually.
Sadler et al. (2015) found no association between vaccination
status and abortion (p D 0.85).48 Another (Lutringer-Magnin
et al., 2013) assessed abortion rates between vaccinated and
unvaccinated groups found that 7.1% of their population had
had an abortion and all of these participants were unvacci-
nated.40 Additionally, a study with a population between 13
and 23 y of age found that unvaccinated women were more
likely to have been pregnant (20% vs. 8.6%, p D 0.016), a result
that runs contrary to the notion of risk compensation.45
Discussion
There have been several studies examining the association
between HPV vaccination using self-report or biological
markers of increased risky sexual behaviors. Twenty studies
were identiﬁed for this systematic review. The included studies
were all published between 2011 and 2015 and varied in study
design and sample size. Each of the studies had limitations and
the results of each individual research effort should be inter-
preted with caution. However, when this body of literature is
examined as a whole, with similar ﬁndings reported across
studies, the consistent and replicated evidence indicates that
HPV vaccination does not lead to risk compensation/sexual
disinhibition. The ﬁnding that adolescents do not appear to
respond to vaccination with increased risky sexual behavior
suggests no support for RHT as applied to HPV vaccination.
This conclusion is supported both by studies that focused on
self-reported sexual behavior as well as studies that examined
biological markers of risk (e.g., STI diagnosis).
Furthermore, there appeared to be more support for the fact
that vaccinated women actually showed less involvement in
risky behaviors than unvaccinated women, which was evi-
denced by lower numbers of sexual partners and increased use
of contraception. This ﬁnding is not entirely surprising in light
of previous research reporting that pro-health behaviors tend
to cluster together, such that a person who engages in one pro-
tective health behavior (e.g., getting vaccinated) is more likely
to engage in another (e.g., using condoms).54 Additionally, an
HPV vaccination visit to a healthcare provider may present
families and providers with opportunities to discuss and pro-
mote health and disease prevention behaviors.
Several studies that examined risk perception merit dis-
cussion, even though they did not meet the inclusion criteria
for the systematic review, and therefore were not presented
in the Results section. Some of these studies examined the
perception of risk in a completely vaccinated sample and
compared a decreased risk perception post-vaccination to
subsequent sexual behaviors. These studies found that vacci-
nated individuals perceived a need for safer sexual behavior
after vaccination.55-57 It is notable that these studies’ ﬁndings
were consistent with the results of studies included in this
review. Furthermore, authors of a recent review of the litera-
ture on HPV vaccine attitudes and uptake found that the
concern about risk compensation following vaccination was
a “myth” rather than a valid concern.58
This systematic review does have limitations so conclusions
must be drawn with caution. First, the studies included are het-
erogeneous in both population and outcome deﬁnitions, which
could reduce the speciﬁcity and precision of the ﬁndings. This
issue is common in systematic reviews of this nature. For
instance, one recent systematic review examining HPV vaccina-
tion or vaccine intent found varied evidence between HPV vac-
cination or vaccine intent and sexual behavior primarily due to
the heterogeneous nature of the included studies.59 At the same
time, the fact that similar results are reported across studies
that varied so widely in methodology and population, suggests
that the ﬁndings of no association between vaccination and sex-
ual risk compensation are robust. Secondly, the desire to engage
in risky sexual behavior might cause a person to seek out vacci-
nation which would make it appear that the vaccinated group
practices more risky sexual behavior. This can be difﬁcult to
assess, particularly in cross-sectional studies because, as some
research has shown, there are times when physicians have vac-
cinated their patients based on perceived risk status.34-36 This
should not be confused with an implication that the vaccination
is the cause of the risky behavior. Finally, this review of the lit-
erature is reliant on the ﬁndings of the studies included in the
review. Each of these individual studies had limitations of their
own including: a lack of a comparison group, recall bias, and
social desirability of responses among others. Nevertheless, this
study thoroughly examined 3 different databases with relevant
search terms in order to capture the appropriate studies. To
our knowledge, this is the ﬁrst systematic review examining the
association (or lack thereof) between HPV vaccination and sub-
sequent sexual behaviors and adds credibility to the literature
by combining the results and showing there is no consistent,
replicated evidence of sexual disinhibition after HPV
vaccination.
Materials and methods
A systematic review of the literature was performed using the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) protocol and searching the PubMed,
CINAHL, and Embase databases. The following search terms
were used: [(sex behavior OR sex behavior OR sexual) AND
(human papillomavirus OR HPV) AND (vaccines OR vaccine
OR vaccination)] and the results were limited to studies from
January 1, 2008 to June 30, 2015. The January 1, 2008 start date
was chosen in order to capture articles examining behaviors
post-vaccination. 4vHPV was ﬁrst licensed in the US in mid-
2006 and the Advisory Committee on Immunization Practices
(ACIP) voted to routinely recommend it for girls in June 2006,
at which point it was covered by the majority of insurers.60
These recommendations were published in the Morbidity and
Mortality Weekly Report in March 2007.61 Therefore, relevant
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research examining post-vaccination behaviors was not pub-
lished until 2010. Nevertheless, the 2008 start date for the
search was chosen as a conservative estimate in order to ensure
that we captured all relevant research.
To answer the outlined research questions, study outcomes
were divided into 2 groups: self-reported behaviors (age at sex-
ual initiation, reported number of sexual partners, and reported
condom usage), and biological outcomes (pregnancy and STI
diagnoses). Articles were included if they examined reported
behaviors and/or biological outcomes post-vaccination. Studies
were not restricted by age, gender, or geographic location.
Articles were excluded if they examined worry or behavioral
intent but not actual behaviors. Studies were also excluded if
they were not original, peer-reviewed research articles (e.g.
published abstracts for conferences, press releases, or commen-
taries on other articles).
First, studies were screened for inclusion by reviewing the
titles and abstracts (MLK & GKS). Additional studies were
excluded by a closer examination of the remaining abstracts
(MLK & GDZ). The remaining studies were examined as full-
text articles. Two authors independently reviewed each study to
determine the relevance for inclusion. Each reviewer completed
a data extraction and quality assessment sheet for each article.
Most of the quality assessment tools for systematic reviews
were developed and validated for intervention research.62-65
The data extraction sheet used in this systematic review was
developed by combining relevant portions of previously vali-
dated data quality assessment tools from the Agency for
Healthcare Research and Quality’s (AHRQ), Cochrane,
PRISMA, and the NIH Quality Assessment Tool for Observa-
tional Cohort and Cross-Sectional Studies.
Conclusion
The consistent, replicated evidence found across the 20 studies
examined in this systematic review provides a strong body of
evidence refuting that there is an association between HPV
vaccination and risky sexual behavior. The 20 different stud-
ies, utilizing at least 4 distinct study designs, and including a
total of 521,879 participants, found no evidence of increased
numbers of sexual partners, younger age of sexual initiation,
decreased use of contraception (including both condoms and
hormonal contraceptives), increased STI diagnoses, increased
pregnancy rates, or increased history of abortion among those
vaccinated against HPV. In fact, some studies found vacci-
nated women showed lower risky behaviors than unvaccinated
women, indicating a tendency toward less risky health behav-
iors. These ﬁndings should alleviate parental and provider
concerns that HPV vaccination will lead to risky sexual behav-
iors. Furthermore, as others have noted, even if risk compen-
sation was identiﬁed as an issue related to HPV vaccination,
this would not be justiﬁcation for withholding vaccination,
but would argue for effective pre- and post-vaccination
counseling.58
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